Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 2, 2023. (Total: 223599Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 7 (of 7 Records)

Query Trace: Lung Neoplasms and GGH[original query]
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Feb 28 (4): 614-9.
Adjei Alex A, Mandrekar Sumithra J, Dy Grace K, Molina Julian R, Adjei Araba A, Gandara David R, Ziegler Katie L Allen, Stella Philip J, Rowland Kendrith M, Schild Steven E, Zinner Ralph
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Sep 5 (9): 1346-53.
Adjei Araba A, Salavaggione Oreste E, Mandrekar Sumithra J, Dy Grace K, Ziegler Katie L Allen, Endo Chiaki, Molina Julian R, Schild Steven E, Adjei Alex
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Dec .
Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Lung cancer (Amsterdam, Netherlands) 2012 Oct 78 (1): 92-9.
Tiseo Marcello, Giovannetti Elisa, Tibaldi Carmelo, Camerini Andrea, Di Costanzo Francesco, Barbieri Fausto, Burgers Jacobus A, Vincent Andrew, Peters Godefridus J, Smit Egbert F, Ardizzoni Andr
Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.
The pharmacogenomics journal 2014 Oct 14 (5): 411-7.
Corrigan A, Walker J L, Wickramasinghe S, Hernandez M A, Newhouse S J, Folarin A A, Lewis C M, Sanderson J D, Spicer J, Marinaki A
Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients.
Frontiers in pharmacology 2019 10 944.
Zhang Xiaoqing, Zhang Di, Huang Lihua, Li Guorong, Chen Luan, Ma Jingsong, Li Mo, Wei Muyun, Zhou Wei, Zhou Chenxi, Zhu Jinhang, Wang Zhanhui, Qin Shengyi
Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer.
Thorax 2021 Apr .
Visser Sabine, Koolen Stijn, van Donk Nadine, van Walree Nico, van der Leest Cor, Cornelissen Robin, van Schaik Ron, Mathijssen Ron, Aerts Joachim, Stricker Bruno
TOP